Cargando…

NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains

Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but do not affect RNA synthesis by pre-formed RCs. Without new RC forma...

Descripción completa

Detalles Bibliográficos
Autores principales: Benzine, Tiffany, Brandt, Ryan, Lovell, William C., Yamane, Daisuke, Neddermann, Petra, De Francesco, Raffaele, Lemon, Stanley M., Perelson, Alan S., Ke, Ruian, McGivern, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464671/
https://www.ncbi.nlm.nih.gov/pubmed/28594932
http://dx.doi.org/10.1371/journal.ppat.1006343
_version_ 1783242820188897280
author Benzine, Tiffany
Brandt, Ryan
Lovell, William C.
Yamane, Daisuke
Neddermann, Petra
De Francesco, Raffaele
Lemon, Stanley M.
Perelson, Alan S.
Ke, Ruian
McGivern, David R.
author_facet Benzine, Tiffany
Brandt, Ryan
Lovell, William C.
Yamane, Daisuke
Neddermann, Petra
De Francesco, Raffaele
Lemon, Stanley M.
Perelson, Alan S.
Ke, Ruian
McGivern, David R.
author_sort Benzine, Tiffany
collection PubMed
description Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but do not affect RNA synthesis by pre-formed RCs. Without new RC formation, existing RCs turn over and are eventually lost from the cell. We aimed to use NS5A inhibitors to estimate the half-life of the functional RC of HCV. We compared different cell culture-infectious strains of HCV that may be grouped based on their sensitivity to lipid peroxidation: robustly replicating, lipid peroxidation resistant (LPO(R)) viruses (e.g. JFH-1 or H77D) and more slowly replicating, lipid peroxidation sensitive (LPO(S)) viruses (e.g. H77S.3 and N.2). In luciferase assays, LPO(S) HCV strains declined under NS5A inhibitor therapy with much slower kinetics compared to LPO(R) HCV strains. This difference in rate of decline was not observed for inhibitors of the NS5B RNA-dependent RNA polymerase suggesting that the difference was not simply a consequence of differences in RNA stability. In further analyses, we compared two isoclonal HCV variants: the LPO(S) H77S.3 and the LPO(R) H77D that differ only by 12 amino acids. Differences in rate of decline between H77S.3 and H77D following NS5A inhibitor addition were not due to amino acid sequences in NS5A but rather due to a combination of amino acid differences in the non-structural proteins that make up the HCV RC. Mathematical modeling of intracellular HCV RNA dynamics suggested that differences in RC stability (half-lives of 3.5 and 9.9 hours, for H77D and H77S.3, respectively) are responsible for the different kinetics of antiviral suppression between LPO(S) and LPO(R) viruses. In nascent RNA capture assays, the rate of RNA synthesis decline following NS5A inhibitor addition was significantly faster for H77D compared to H77S.3 indicating different half-lives of functional RCs.
format Online
Article
Text
id pubmed-5464671
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54646712017-06-22 NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains Benzine, Tiffany Brandt, Ryan Lovell, William C. Yamane, Daisuke Neddermann, Petra De Francesco, Raffaele Lemon, Stanley M. Perelson, Alan S. Ke, Ruian McGivern, David R. PLoS Pathog Research Article Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but do not affect RNA synthesis by pre-formed RCs. Without new RC formation, existing RCs turn over and are eventually lost from the cell. We aimed to use NS5A inhibitors to estimate the half-life of the functional RC of HCV. We compared different cell culture-infectious strains of HCV that may be grouped based on their sensitivity to lipid peroxidation: robustly replicating, lipid peroxidation resistant (LPO(R)) viruses (e.g. JFH-1 or H77D) and more slowly replicating, lipid peroxidation sensitive (LPO(S)) viruses (e.g. H77S.3 and N.2). In luciferase assays, LPO(S) HCV strains declined under NS5A inhibitor therapy with much slower kinetics compared to LPO(R) HCV strains. This difference in rate of decline was not observed for inhibitors of the NS5B RNA-dependent RNA polymerase suggesting that the difference was not simply a consequence of differences in RNA stability. In further analyses, we compared two isoclonal HCV variants: the LPO(S) H77S.3 and the LPO(R) H77D that differ only by 12 amino acids. Differences in rate of decline between H77S.3 and H77D following NS5A inhibitor addition were not due to amino acid sequences in NS5A but rather due to a combination of amino acid differences in the non-structural proteins that make up the HCV RC. Mathematical modeling of intracellular HCV RNA dynamics suggested that differences in RC stability (half-lives of 3.5 and 9.9 hours, for H77D and H77S.3, respectively) are responsible for the different kinetics of antiviral suppression between LPO(S) and LPO(R) viruses. In nascent RNA capture assays, the rate of RNA synthesis decline following NS5A inhibitor addition was significantly faster for H77D compared to H77S.3 indicating different half-lives of functional RCs. Public Library of Science 2017-06-08 /pmc/articles/PMC5464671/ /pubmed/28594932 http://dx.doi.org/10.1371/journal.ppat.1006343 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Benzine, Tiffany
Brandt, Ryan
Lovell, William C.
Yamane, Daisuke
Neddermann, Petra
De Francesco, Raffaele
Lemon, Stanley M.
Perelson, Alan S.
Ke, Ruian
McGivern, David R.
NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
title NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
title_full NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
title_fullStr NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
title_full_unstemmed NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
title_short NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
title_sort ns5a inhibitors unmask differences in functional replicase complex half-life between different hepatitis c virus strains
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464671/
https://www.ncbi.nlm.nih.gov/pubmed/28594932
http://dx.doi.org/10.1371/journal.ppat.1006343
work_keys_str_mv AT benzinetiffany ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT brandtryan ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT lovellwilliamc ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT yamanedaisuke ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT neddermannpetra ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT defrancescoraffaele ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT lemonstanleym ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT perelsonalans ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT keruian ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains
AT mcgiverndavidr ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains